Cristian Alejandro Valenzuela‐Oñate

Dr. Cristian Alejandro Valenzuela‐Oñate


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
JOJosé María Ortiz‐Salvador
José María Ortiz‐Salvador
ÁMÁlvaro Martínez‐Doménech
Álvaro Martínez‐Doménech
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
APAmparo Pérez‐Ferriols
Amparo Pérez‐Ferriols

25 November 2019 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
MGMarta García‐Legaz‐Martínez
Marta García‐Legaz‐Martínez
ÁMÁlvaro Martínez‐Domenech
Álvaro Martínez‐Domenech
APAmparo Pérez‐Ferriols
Amparo Pérez‐Ferriols

11 February 2020 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
MAMiriam Alonso‐Carpio
Miriam Alonso‐Carpio
MGMarta García‐Legaz
Marta García‐Legaz
VMVíctor Alegre‐De Miquel
Víctor Alegre‐De Miquel
VZVioleta Zaragoza‐Ninet
Violeta Zaragoza‐Ninet

8 May 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
MMMarta Garcia‐Legaz Martínez
Marta Garcia‐Legaz Martínez
GPGemma Perez‐Pastor
Gemma Perez‐Pastor
JCJosé Luis Sanchez Carazo
José Luis Sanchez Carazo
Sonic hedgehog pathway inhibitor Vismodegib is the first systemic treatment to be approved for metastatic or locally advanced basal cell carcinoma (BCC) non‐subsidiary of surgical treatment, and appears to be a promising treatment option for patients with nevoid basal cell carcinoma syndrome (NBCCS). In these patients, where repeated or prolonged treatment may be necessary, the psychological exhaustion caused by the chronicity of less severe adverse effects appears as the main limiting factor in the persistence of the drug in the long term and in the willingness of patients to take the drug again after its suspension. We report our experience with three cases where a drug holiday approach was effective in decreasing the intensity of adverse effects or improving the patient's subjective tolerance to the drug while maintaining clinical response.

26 June 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MMMarta García‐Legaz Martínez
Marta García‐Legaz Martínez
ÁMÁlvaro Martínez‐Doménech
Álvaro Martínez‐Doménech
JMJorge Magdaleno‐Tapial
Jorge Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
FPFelipe Partarrieu‐Mejías
Felipe Partarrieu‐Mejías
VMVíctor Alegre‐De Miquel
Víctor Alegre‐De Miquel
Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2), was first reported in China on December 2019. Almost 5 months into the pandemic, little is still known about cutaneous manifestations in COVID‐19. In fact, the prevalence of cutaneous signs varies greatly in the literature, ranging from 0.2% to 20.4%. Given their potential association with COVID‐19, acral lesions have received special attention worldwide, both in the medical literature and the media. Our aim is to share our experience regarding acral manifestations during this pandemic.

25 June 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JMJ. Magdaleno‐Tapial
J. Magdaleno‐Tapial
CVCristian Alejandro Valenzuela‐Oñate
Cristian Alejandro Valenzuela‐Oñate
AMA. Martínez‐Doménech
A. Martínez‐Doménech
JSJ.L. Sánchez‐Carazo
J.L. Sánchez‐Carazo
APA. Pérez‐Ferriols
A. Pérez‐Ferriols
Click on the article title to read more.